Skip to main content
PMC home page
Gut logoLink to Gut
. 1994;35(3 Suppl):S1–S4. doi: 10.1136/gut.35.3_suppl.s1

Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.

A G Harris 1
PMCID: PMC1374387  PMID: 7911441

Abstract

Somatostatin is a 14 amino acid peptide that inhibits pancreatic exocrine and endocrine secretion. Its clinical application has been limited by its very short half life, necessitating continuous intravenous infusion. Octreotide is an 8 amino acid synthetic analogue of somatostatin that possesses similar pharmacological effects. It has a much longer duration of action, however, and can be given subcutaneously. Both the intravenous and subcutaneous routes of injection of octreotide are well tolerated. Peak serum concentrations occur within 30 minutes after subcutaneous administration and within four minutes of a three minute intravenous infusion. Serum concentration increases linearly with dose. Octreotide is distributed rapidly, mainly in the plasma, where it is 65% protein bound. The elimination half life is about 1.5 hours and about 32% of a subcutaneous dose is excreted in the urine as unchanged octreotide. Octreotide inhibits gastroenteropancreatic secretion, especially of insulin, glucagon, pancreatic polypeptide, gastric inhibitory polypeptide, and gastrin. It also inhibits both release of thyroid stimulating hormone and growth hormone secretion in response to exercise, insulin induced hypoglycaemia, and argenine stimulation. Octreotide reduces splanchnic blood flow in healthy volunteers and hepatic venous pressure in cirrhotic patients. It can accelerate or delay gastric emptying, prolong transit time at moderate to high doses, stimulate motility at low doses, and inhibit gall bladder emptying. Octreotide considerably inhibits pentagastrin stimulated gastric acid secretion and significantly diminishes exocrine pancreatic function (amylase, trypsin, lipase). Octreotide increases intestinal transit time and decreases endogenous fluid secretion in the jejunum and ileum, thus increasing the absorption of water and electrolytes.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
S1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold R., Lankisch P. G. Somatostatin and the gastrointestinal tract. Clin Gastroenterol. 1980 Sep;9(3):733–753. [PubMed] [Google Scholar]
  2. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., Petcher T. J., Pless SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982 Sep 13;31(11):1133–1140. doi: 10.1016/0024-3205(82)90087-x. [DOI] [PubMed] [Google Scholar]
  3. Bausher L. P., Horio B. Neuropeptide Y and somatostatin inhibit stimulated cyclic AMP production in rabbit ciliary processes. Curr Eye Res. 1990 Apr;9(4):371–378. doi: 10.3109/02713689008999625. [DOI] [PubMed] [Google Scholar]
  4. Bloom S. R., Mortimer C. H., Thorner M. O., Besser G. M., Hall R., Gomez-Pan A., Roy V. M., Russell R. C., Coy D. H., Kastin A. J. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet. 1974 Nov 9;2(7889):1106–1109. doi: 10.1016/s0140-6736(74)90869-1. [DOI] [PubMed] [Google Scholar]
  5. Bloom S. R., Ralphs D. N., Besser G. M., Hall R., Coy D. H., Kastin A. J., Schally A. V. Proceedings: Effect of somatostatin on motilin levels and gastric emptying. Gut. 1975 Oct;16(10):834–834. [PubMed] [Google Scholar]
  6. Boden G., Sivitz M. C., Owen O. E., Essa-Koumar N., Landor J. H. Somatostatin suppresses secretin and pancreatic exocrine secretion. Science. 1975 Oct 10;190(4210):163–165. doi: 10.1126/science.1166308. [DOI] [PubMed] [Google Scholar]
  7. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973 Jan 5;179(4068):77–79. doi: 10.1126/science.179.4068.77. [DOI] [PubMed] [Google Scholar]
  8. Brown M., Rivier J., Vale W. Somatostatin-28: selective action on the pancreatic beta-cell and brain. Endocrinology. 1981 Jun;108(6):2391–2396. doi: 10.1210/endo-108-6-2391. [DOI] [PubMed] [Google Scholar]
  9. Cai R. Z., Szoke B., Lu R., Fu D., Redding T. W., Schally A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1896–1900. doi: 10.1073/pnas.83.6.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dollinger H. C., Raptis S., Pfeiffer E. F. Effects of somatostatin on exocrine and endocrine pancreatic function stimulated by intestinal hormones in man. Horm Metab Res. 1976 Jan;8(1):74–78. doi: 10.1055/s-0028-1093677. [DOI] [PubMed] [Google Scholar]
  11. Dubois M. P. Immunoreactive somatostatin is present in discrete cells of the endocrine pancreas. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1340–1343. doi: 10.1073/pnas.72.4.1340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dueno M. I., Bai J. C., Santangelo W. C., Krejs G. J. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci. 1987 Oct;32(10):1092–1096. doi: 10.1007/BF01300194. [DOI] [PubMed] [Google Scholar]
  13. Gottesman I., Tobert J., Vandlen R., Gerich J. Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L-363,586) in insulin-dependent diabetes mellitus. Life Sci. 1986 Jun 16;38(24):2211–2219. doi: 10.1016/0024-3205(86)90573-4. [DOI] [PubMed] [Google Scholar]
  14. Gyr K. E., Whitehouse I., Beglinger C., Köhler E., Dettwiler S., Fried M. Human pharmacological effects of SMS 201-995 on gastric secretion. Scand J Gastroenterol Suppl. 1986;119:96–102. doi: 10.3109/00365528609087436. [DOI] [PubMed] [Google Scholar]
  15. Jackson J. A., Hahn H. B., Jr, Oltorf C. E., O'Dorisio T. M., Vinik A. I. Long-term treatment of refractory neonatal hypoglycemia with long-acting somatostatin analog. J Pediatr. 1987 Oct;111(4):548–551. doi: 10.1016/s0022-3476(87)80118-x. [DOI] [PubMed] [Google Scholar]
  16. Jaros W., Biller J., Greer S., O'Dorisio T., Grand R. Successful treatment of idiopathic secretory diarrhea of infancy with the somatostatin analogue SMS 201-995. Gastroenterology. 1988 Jan;94(1):189–193. doi: 10.1016/0016-5085(88)90629-4. [DOI] [PubMed] [Google Scholar]
  17. Johnston D. G., Davies R. R., Turner S. J. Effects of somatostatin and SMS 201-995 on carbohydrate metabolism in normal man. Scand J Gastroenterol Suppl. 1986;119:158–165. doi: 10.3109/00365528609087445. [DOI] [PubMed] [Google Scholar]
  18. Konturek S. J., Tasler J., Obtulowicz W., Coy D. H., Schally A. V. Effect of growth hormone-release inhibiting hormone on hormones stimulating exocrine pancreatic secretion. J Clin Invest. 1976 Jul;58(1):1–6. doi: 10.1172/JCI108438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kraicer J., Spence J. W. Release of growth hormone from purified somatotrophs: use of high K+ and the ionophore A23187 to elucidate interrelations among Ca++, adenosine 3',5'-monophosphate, and somatostatin. Endocrinology. 1981 Feb;108(2):651–657. doi: 10.1210/endo-108-2-651. [DOI] [PubMed] [Google Scholar]
  20. Lamberts S. W., Oosterom R., Neufeld M., del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 1985 Jun;60(6):1161–1165. doi: 10.1210/jcem-60-6-1161. [DOI] [PubMed] [Google Scholar]
  21. Lamireau T., Galpérine R. I., Ohlbaum P., Demarquez J. L., Vergnes P., Kurzenne Y., Hehunstre J. P. Use of a long acting somatostatin analogue in controlling ileostomy diarrhoea in infants. Acta Paediatr Scand. 1990 Aug-Sep;79(8-9):871–872. doi: 10.1111/j.1651-2227.1990.tb11572.x. [DOI] [PubMed] [Google Scholar]
  22. Larsson L. I., Goltermann N., de Magistris L., Rehfeld J. F., Schwartz T. W. Somatostatin cell processes as pathways for paracrine secretion. Science. 1979 Sep 28;205(4413):1393–1395. doi: 10.1126/science.382360. [DOI] [PubMed] [Google Scholar]
  23. Layer P., vd Ohe M., Müller M. K., Beglinger C. Effects of somatostatin on the exocrine pancreas. Scand J Gastroenterol. 1991 Feb;26(2):129–136. doi: 10.3109/00365529109025022. [DOI] [PubMed] [Google Scholar]
  24. Lembcke B., Creutzfeldt W., Schleser S., Ebert R., Shaw C., Koop I. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion. 1987;36(2):108–124. doi: 10.1159/000199408. [DOI] [PubMed] [Google Scholar]
  25. Luft R., Efendić S., Hökfelt T. Somatostatin--both hormone and neurotransmitter? Diabetologia. 1978 Jan 14;14(1):1–13. doi: 10.1007/BF00429702. [DOI] [PubMed] [Google Scholar]
  26. McNellis E. L., Bausher L. P. Stimulatory and inhibitory cyclic AMP responses in rabbit ciliary processes after cervical ganglionectomy. Curr Eye Res. 1991 May;10(5):399–407. doi: 10.3109/02713689109001748. [DOI] [PubMed] [Google Scholar]
  27. Mehler P. S., Sussman A. L., Maman A., Leitner J. W., Sussman K. E. Role of insulin secretagogues in the regulation of somatostatin binding by isolated rat islets. J Clin Invest. 1980 Dec;66(6):1334–1338. doi: 10.1172/JCI109986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ohlbaum P., Galperine R. I., Demarquez J. L., Vergnes P., Martin C. Use of a long-acting somatostatin analogue (SMS 201-995) in controlling a significant ileal output in a 5-year-old child. J Pediatr Gastroenterol Nutr. 1987 May-Jun;6(3):466–470. doi: 10.1097/00005176-198705000-00026. [DOI] [PubMed] [Google Scholar]
  29. Penman E., Wass J. A., Butler M. G., Penny E. S., Price J., Wu P., Rees L. H. Distribution and characterisation of immunoreactive somatostatin in human gastrointestinal tract. Regul Pept. 1983 Sep;7(1):53–65. doi: 10.1016/0167-0115(83)90281-1. [DOI] [PubMed] [Google Scholar]
  30. Polak J. M., Pearse A. G., Grimelius L., Bloom S. R. Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet. 1975 May 31;1(7918):1220–1222. doi: 10.1016/s0140-6736(75)92198-4. [DOI] [PubMed] [Google Scholar]
  31. Pradayrol L., Jörnvall H., Mutt V., Ribet A. N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Lett. 1980 Jan 1;109(1):55–58. doi: 10.1016/0014-5793(80)81310-x. [DOI] [PubMed] [Google Scholar]
  32. Rosenthal L. E., Yamashiro D. J., Rivier J., Vale W., Brown M., Dharmsathaphorn K. Structure-activity relationships of somatostatin analogs in the rabbit ileum and the rat colon. J Clin Invest. 1983 Apr;71(4):840–849. doi: 10.1172/JCI110838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Vale W., Rivier J., Ling N., Brown M. Biologic and immunologic activities and applications of somatostatin analogs. Metabolism. 1978 Sep;27(9 Suppl 1):1391–1401. doi: 10.1016/0026-0495(78)90081-1. [DOI] [PubMed] [Google Scholar]
  34. Veber D. F., Freidlinger R. M., Perlow D. S., Paleveda W. J., Jr, Holly F. W., Strachan R. G., Nutt R. F., Arison B. H., Homnick C., Randall W. C. A potent cyclic hexapeptide analogue of somatostatin. Nature. 1981 Jul 2;292(5818):55–58. doi: 10.1038/292055a0. [DOI] [PubMed] [Google Scholar]
  35. Veber D. F., Holly F. W., Nutt R. F., Bergstrand S. J., Brady S. F., Hirschmann R., Glitzer M. S., Saperstein R. Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature. 1979 Aug 9;280(5722):512–514. doi: 10.1038/280512a0. [DOI] [PubMed] [Google Scholar]
  36. Wahren J. Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus. Lancet. 1976 Dec 4;2(7997):1213–1216. doi: 10.1016/s0140-6736(76)91142-9. [DOI] [PubMed] [Google Scholar]
  37. Williams G., Ball J. A., Burrin J. M., Joplin G. F., Bloom S. R. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. Lancet. 1986 Oct 4;2(8510):774–778. doi: 10.1016/s0140-6736(86)90300-4. [DOI] [PubMed] [Google Scholar]
  38. Williams G., Fuessl H., Kraenzlin M., Bloom S. R. Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance. Scand J Gastroenterol Suppl. 1986;119:73–83. doi: 10.3109/00365528609087434. [DOI] [PubMed] [Google Scholar]
  39. Wilson D. C., Carson D. J., Quinn R. J. Long-term use of somatostatin analogue SMS 201-995 in the treatment of hypoglycaemia due to nesidioblastosis. Acta Paediatr Scand. 1988 May;77(3):467–470. doi: 10.1111/j.1651-2227.1988.tb10683.x. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES